Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: A pilot study

Kidney International

Volumn 70, Issue 1, 2006, Pages 192-198

  Evenepoel, P ^a,b   Bammens, B ^a   Verbeke, K ^b   Vanrenterghem, Y ^a  

^a Division of Nephrology   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Acarbose; Kidney disease; p cresol; Protein fermentation; Protein bound solutes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; CREATININE; FERROUS GLUCONATE; NITROFURANTOIN; NITROGEN; PARA CRESOL; PERENTEROL;

ADULT; ARTICLE; BACTERIAL METABOLISM; BLOATING; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; COLON FLORA; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFECT; FECES ANALYSIS; FEMALE; FERMENTATION; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; MALE; NITROGEN URINE LEVEL; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; SOLUTE; URINALYSIS; VOLUNTEER;

ACARBOSE; ADULT; ALPHA-GLUCOSIDASES; BLOOD PROTEINS; CRESOLS; ENZYME INHIBITORS; FECES; GASTROINTESTINAL TRACT; HUMANS; MALE; PILOT PROJECTS;

EID: 33745725902     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001523     Document Type: Article

References (58)

1. Vanholder R, De Smet R, Lameire N. Uremic toxicity. In: Hörl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF (eds), Replacement of Renal Function by Dialysis, 5th edn. Kluwer Academic Publishers: Dordrecht, The Netherlands, 2004, pp 15-55.
2. Vanholder R, De Smet R, Glorieux R et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
3. Vanholder R, De Smet R, Waterloos MA et al. Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int 1995; 47: 510-517.
4. Wratten ML, Tetta C, De Smet R et al. Uremic ultrafiltrate inhibits platelet-activating factor synthesis. Blood Purif 1999; 17: 134-141.
5. Dou L, Cerini C, Brunet P et al. p-Cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 2002; 62: 1999-2009.
6. Dou L, Bertrand E, Cerini C et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451.
7. Motojima M, Hosokawa A, Yamato H et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-κB and free radical in proximal tubular cells. Kidney Int 2003; 63: 1671-1680.
8. Jankowski J, van der Giet M, Jankowski V et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 2003; 112: 256-264.
9. Niwa T. Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 1996; 16: 167-182.
10. De Smet R, Van Kaer J, Van Vlem B et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 2003; 49: 470-478.
11. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64: 2238-2243.
12. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320.
13. Eknoyan G, Beck G, Cheung A et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
14. Locatelli F. Dose of dialysis, convection and haemodialysis patients outcome -what the HEMO study doesn't tell us: the European viewpoint. Nephrol Dial Transplant 2003; 18: 1061-1065.
15. Levin N, Greenwood R. Reflections on the HEMO study: the American viewpoint. Nephrol Dial Transplant 2003; 18: 1059-1060.
16. Lesaffer G, De Smet R, Lameire N et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000; 15: 50-57.
17. Fagugli RM, De Smet R, Buoncristiani U et al. Behavior of non-protein-bound and protein-bound solutes during daily hemodialysis. Am J Kidney Dis 2002; 40: 339-347.
18. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004; 44: 278-285.
19. Evenepoel P, Maes B, Wilmer A et al. Detoxifying capacity and kinetics of the Molecular Adsorbent Recycling System Contribution of the different inbuilt filters. Blood Purif 2003; 21: 244-252.
20. Smith EA, Macfarlane GT. Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J Appl Bact 1996; 81: 288-302.
21. Birkett A, Muir J, Phillips J et al. Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr 1996; 63: 766-772.
22. Macfarlane GT, Cummings JH. The colonic flora, fermentation and large bowel digestive function. In: Phillips SF, Pemberton H, Shorter RG (eds), The Large Intestine: Physiology, Pathophysiology and Disease. Raven Press: New York, NY, USA, 1991, pp 51-92.
23. Vince A, Dawson AM, Park N, O'Grady F. Ammonia production by intestinal bacteria. Gut 1973; 14: 171-177.
24. Vince AJ, Burrigde SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol 1980; 13: 177-191.
25. Vince A, Killingsley M, Wrong OM. Effect of lactulose on ammonia production in a fecal incubation system. Gastroenterology 1978; 74: 544-549.
26. Vince AJ, McNeil NI, Wager JD, Wrong OM. The effect of lactulose, pectin, arabinogalactan and cellulose on the production of organic acids and metabolism of ammonia by intestinal bacteria in a faecal incubation system. Br J Nutr 1990; 63: 17-26.
27. Bisschoff H. Pharmacology of alfa-glucosidase inhibition. Eur J Clin Invest 1994; 24(Suppl 3): 3-10.
28. Hiele M, Ghoos Y, Rutgeerts P, Vantrappen G. Effects of acarbose on starch hydrolysis. Study in healthy subjects, ileostomy patients, and in vitro. Dig Dis Sci 1992; 37: 1057-1064.
29. Sobajima H, Mori M, Niwa T et al. Carbohydrate malabsorption following acarbose administration. Diabet Med 1998; 15: 393-397.
30. Creutzfeldt W. Effects of the alfa-glucosidase inhibitor acarbose on the development of long-term complications in diabetic animals: pathophysiological and therapeutic complications. Diabetes Metab Res Rev 1999; 15: 289-296.
31. Sato H, Shiina N. Effect of an alfa-glucosidase inhibitor on glomerular basement membrane anionic sites in streptozotocin induced mildly diabetic rats. Diabetes Res Clin Pract 1997; 37: 91-99.
32. Reuser AJJ, Wisselaar HA. An evaluation of the potential side-effects of alfa-glucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest 1994; 24(Suppl 3): 19-24.
33. Wolin MJ, Miller TL, Yerry S et al. Changes of fermentation pathways of fecal microbial communities associated with a drug treatment that increases dietary starch in the human colon. Appl Environ Microbiol 1999; 65: 2807-2812.
34. Weaver GA, Tangel CT, Krause JA et al. Acarbose enhances human colonic butyrate production. J Nutr 1997; 127: 717-723.
35. Kast RE. Acarbose related diarrhea: increased butyrate upregulates prostaglandin E. Inflamm Res 2002; 51: 117-118.
36. Cummings JH, Hill MJ, Bone ES et al. The effect of meat protein and dietary fiber on colonic function and metabolism II. Bacterial metabolites in feces and urine. Am J Clin Nutr 1979; 32: 2094-2101.
37. Sunder-Plassmann G, Patruta SI, Hörl WH. Pathobiology of the role of iron in infection. Am J Kidney Dis 1999; 34(Suppl 2): S25-S29.
38. Benoni G, Cuzzolin L, Zambreri D et al. Desferrioxamine potentiated SOD antiinflammatory activity in rat adjuvant arthritis: role of iron and bacterial toxins. Agents Actions 1992 (Spec. No.): C112-C114.
39. Cerini C, Dou L, Anfosso F et al. p-Cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 2004; 92: 140-150.
40. de Loor H, Bammens B, Evenepoel P et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51: 1535-1538.
41. Martinez AW, Recht NS, Hostetter TH, Meyer TW. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-3436.
42. Bammens B, Evenepoel P, Keuleers H et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087.
43. Campbell RA. Polyamines and atherosclerosis. Lancet 1979; 1: 724-725.
44. Bagdade JD, Subbaiah PV, Bartos D et al. Polyamines: an unrecognised cardiovascular risk factor in chronic dialysis. Lancet 1979; 1: 412-413.
45. MacDougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int 2001; 59(Suppl 78): S67-S72.
46. Kushner D, Beckman B, Nguyen L et al. Polyamines in the anemia of end-stage renal disease. Kidney Int 1991; 39: 725-732.
47. Malaguarnera M, Giugno I, Ruello P et al. Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias. Br J Clin Pharmacol 1999; 48: 605-609.
48. Bischoff H. The mechanism of alpha-glucosidase inhibition in the management of diabetes. Clin Invest Med 1995; 18: 303-311.
49. Retarding the progression of renal disease. Kidney Int 2003; 64: 370-378.
50. Guarner F. Gut flora in health and disease. Lancet 2003; 361: 512-519.
51. Hollander P. Safety profile of acarbose, an alfa-glucosidase inhibitor. Drugs 1992; 44(Suppl 2): 47-53.
52. Harrower ADB. Pharmacokinetics of oral antihyperglycemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996; 31: 111-119.
53. Niwa T, Ise M, Miyazaki T, Meada K. Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 1993; 65: 82-87.
54. Hida M, Aiba Y, Sawamura S et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin®, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355.
55. Evenepoel P, Claus D, Geypens B et al. Amount and fate of egg protein escaping assimilation in the small intestine of humans. Am J Physiol 1999; 277: G935-G943.
56. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. Am J Clin Nutr 2004; 80: 1536-1543.
57. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27: 58-65.
58. Stephen AM, Cummings JH. The microbial contribution to human faecal mass. J Med Microbiol 1980; 13: 45-56.